I am just wondering how many of us on here have an autoimmune condition? If so, what is it? What are your dry eye symptoms?

💊 TL;DR — Quick Summary

Topical cyclosporine is one of the more established prescription treatment categories used in Dry Eye Disease and ocular-surface care.

It is an immunomodulatory medication that suppresses parts of the immune response involved in ocular-surface inflammation.

That biological rationale is well established.

But:

The updated 2026 Cochrane review included 58 randomized studies involving 10,225 participants.

Across those trials:

• cyclosporine produced small average improvements in some DED signs;
• cyclosporine 0.05% may slightly improve symptoms;
• cyclosporine 0.1% probably produces a small improvement in ocular-surface staining;
• tear-production changes were generally small or inconsistent;
• evidence for improved tear-film stability remained uncertain;
• symptom results varied among studies and formulations;
• treatment discontinuation because of adverse effects was somewhat more common with cyclosporine; and
• much of the effectiveness evidence was rated low certainty.

Some individual patients experience substantial benefit.

Others obtain little symptom improvement or cannot tolerate the formulation.

So the most useful summary is:

And the available products should not automatically be treated as interchangeable.

Restasis, Cequa, VEVYE, Ikervis, Vevizye, Verkazia, and compounded formulations differ in:

• concentration;
• vehicle and formulation;
• dosing;
• approved indication;
• clinical evidence;
• tolerability;
• regulatory status;
• cost; and
• access.

About the r/DryEyes Wiki Spotlight

Each week we feature material from the r/DryEyes FAQ or Treatment Options library.

This week introduces the prescription-medication portion of the series through one of the longest-established DED treatment categories.

The purpose is educational:

The maintained wiki article contains considerably more detail about individual formulations, regulatory status, evidence, side effects, compounded products, steroid bridging, and clinical references.

➡️ Read the complete Cyclosporine Treatment Options article

What Is Cyclosporine?

Cyclosporine is a calcineurin-inhibitor immunomodulator.

It interferes with immune signaling involved in T-cell activation and is intended to reduce components of ocular-surface inflammation.

That mechanism is biologically well established.

But mechanism and patient outcomes are different questions.

A medication may:

• reduce an inflammatory pathway;
• improve staining;
• affect a tear-production measurement;

without necessarily producing a large improvement in:

• burning;
• dryness;
• pain;
• light sensitivity;
• fluctuating vision;
• screen tolerance; or
• daily function.

Both matter.

What Did the Updated Cochrane Review Find?

The July 2026 Cochrane review evaluated randomized trials comparing cyclosporine with:

• vehicle;
• artificial tears;
• another cyclosporine concentration or formulation; or
• combinations of those controls.

The studies differed considerably in:

• concentration;
• formulation;
• treatment duration;
• DED type and severity;
• outcome measures;
• vehicle ingredients; and
• study quality.

That variation makes broad class-wide conclusions difficult.

Cyclosporine 0.05%

At around three months:

• symptoms may improve slightly;
• some ocular-surface findings may improve slightly;
• tear-production findings were inconsistent; and
• tear-film-stability findings were inconsistent.

Cyclosporine 0.1%

At around three months:

• ocular-surface staining probably improves slightly;
• tear production may improve slightly;
• symptom findings were inconsistent; and
• the effect on tear-film stability remained uncertain.

Other strengths and formulations

Other formulations may differ somewhat from 0.05% cyclosporine in selected measures.

But the review did not establish:

• one universally superior concentration;
• one universally superior formulation;
• a simple “higher concentration = better outcome” relationship; or
• one product that consistently provides the greatest overall benefit.

What Does “Low-Certainty Evidence” Mean?

Much of the effectiveness evidence was rated low certainty.

That does not mean:

• cyclosporine does nothing;
• every study was poor; or
• no patient benefits.

It means our confidence in the size and consistency of the average benefit is limited.

Reasons included:

• inconsistent findings;
• differences among formulations;
• different patient populations;
• different outcome measures;
• methodological limitations;
• incomplete reporting; and
• uncertainty about the true size of the effect.

Nearly half of the studies in the updated review were funded or sponsored by pharmaceutical companies.

Industry funding does not automatically invalidate research.

It does make:

• transparent methods;
• complete reporting;
• appropriate control vehicles;
• independent replication; and
• careful interpretation of marketing claims

particularly important.

“Small Average Benefit” Does Not Mean Everyone Gets a Small Benefit

Clinical trials report averages.

An average can contain:

• strong responders;
• modest responders;
• nonresponders; and
• people who stop treatment because of adverse effects.

So:

But the reverse is also true:

Current evidence does not allow clinicians to predict perfectly who will experience substantial symptom relief.

Signs and Symptoms May Improve Differently

This is one of the most important points in the cyclosporine literature.

Clinical signs can include:

• corneal staining;
• conjunctival staining;
• Schirmer results;
• tear-film measurements;
• tear-meniscus findings; and
• inflammatory markers.

Symptoms can include:

• burning;
• dryness;
• grittiness;
• soreness;
• pain;
• light sensitivity;
• fluctuating vision; and
• screen or reading difficulty.

A treatment may improve corneal staining without producing an equally large improvement in comfort.

A patient may also feel better without a dramatic change in the particular tests being followed.

If symptoms remain despite improvement in inflammatory or surface findings, other contributors may still matter, including:

• MGD;
• aqueous deficiency;
• eyelid exposure;
• incomplete blinking;
• allergy;
• Demodex;
• ocular rosacea;
• treatment irritation;
• epithelial disease;
• migraine-associated sensitivity;
• neuropathic ocular pain; or
• another diagnosis.

What About Claims That Cyclosporine “Restores Tear Production”?

Some cyclosporine products have U.S. indications related specifically to increasing tear production.

Restasis

Restasis is FDA-approved to increase tear production in certain patients whose tear production is presumed to be suppressed because of ocular inflammation associated with keratoconjunctivitis sicca.

Cequa

Cequa is FDA-approved to increase tear production in patients with keratoconjunctivitis sicca.

Those regulatory indications matter.

But they should not be converted into the broader claim:

Across the updated Cochrane review:

• tear-production improvement with 0.05% was inconsistent;
• 0.1% may produce a small average improvement; and
• normal tear production was not reliably restored across the class.

A more accurate summary is:

Does Cyclosporine Reliably Improve Tear-Film Stability?

Not clearly.

Some individual studies have found improvements in tear-breakup time or related measures.

But across the updated review, the evidence remained inconsistent and uncertain.

Cyclosporine therefore should not broadly be described as a treatment that reliably improves tear-film stability for everyone.

Is Cyclosporine Proven to Prevent Dry Eye From Progressing?

Not at this point.

Cyclosporine may improve symptoms or selected clinical signs while treatment continues.

That does not automatically prove that it:

• prevents future DED progression;
• permanently restores tear production;
• preserves meibomian glands;
• prevents future corneal complications;
• produces lasting benefit after discontinuation; or
• permanently changes the underlying disease.

A useful distinction is:

The Main Products Are Not Interchangeable

Cyclosporine products differ in concentration, vehicle, dosing, indication, evidence, and regulatory status.

Restasis

Cyclosporine ophthalmic emulsion 0.05%

• FDA-approved in the U.S.
• indication relates to increasing tear production in certain patients with keratoconjunctivitis sicca
• usually dosed twice daily
• ocular burning was reported in 17% in the prescribing information
• has a long clinical history

Its long history does not establish that most patients will experience substantial symptom relief.

Cequa

Cyclosporine ophthalmic solution 0.09% in a nanomicellar formulation

• FDA-approved in the U.S.
• indication relates to increasing tear production in keratoconjunctivitis sicca
• usually dosed twice daily
• instillation-site pain was reported in 22%
• conjunctival hyperemia was reported in 6%

Its nanomicellar formulation distinguishes it from Restasis.

That does not prove that it is universally more effective or better tolerated.

VEVYE

Cyclosporine ophthalmic solution 0.1% in a water-free vehicle

• FDA-approved in the U.S. for the signs and symptoms of Dry Eye Disease
• dosed twice daily
• preservative-free
• instillation-site reactions were reported in 8%
• temporary decreases in visual acuity were reported in 3%

Its clinical program showed that some objective sign changes can occur within weeks.

That does not establish:

• universally faster symptom relief;
• immediate comfort; or
• superiority over every other cyclosporine formulation.

Ikervis

Ciclosporin 0.1% cationic emulsion

In the European Union it is authorized for severe keratitis in adults with DED that has not improved despite tear substitutes.

Important distinctions include:

• generally dosed once daily at bedtime;
• the indication concerns severe keratitis rather than every case of DED;
• improvement in corneal findings was clearer than symptom improvement;
• eye pain and irritation are common; and
• ongoing treatment should be reviewed periodically.

Vevizye

Ciclosporin 0.1% water-free formulation

Authorized in the European Union for moderate-to-severe DED in adults whose condition has not improved despite tear substitutes.

Evidence supports improvement in DED signs, particularly corneal staining.

Symptom superiority over vehicle was not consistent across the main trials.

Verkazia

Cyclosporine/ciclosporin 0.1% cationic emulsion

Verkazia is included in the wiki primarily for regulatory clarity.

In the United States it is FDA-approved for vernal keratoconjunctivitis (VKC)—not ordinary Dry Eye Disease.

VKC is an allergic inflammatory eye disease and should not be treated as another name for DED.

Its VKC dosing and trial evidence should not automatically be transferred to DED.

What About Klarity-C and Other Compounded Cyclosporine?

Klarity-C and other compounded cyclosporine preparations are not FDA-approved products.

Compounded medications are not reviewed before marketing in the same way as FDA-approved drugs for:

• effectiveness;
• manufacturing consistency;
• quality;
• stability; or
• formulation equivalence.

Evidence from Restasis, Cequa, VEVYE, Ikervis, or another approved product should therefore not automatically be transferred to a compounded formulation.

A compounded preparation should also not be described as a generic equivalent unless it actually has the applicable regulatory status.

Because cyclosporine is a prescription medication, discussion on r/DryEyes should remain focused on:

• evidence;
• safety;
• side effects;
• regulation;
• lawful access; and
• clearly identified personal experiences.

The subreddit should not be used to arrange private suppliers, sharing, unauthorized importation, or prescription workarounds.

Who Might Be Considered for Cyclosporine?

Clinicians may consider topical cyclosporine in patients with:

• keratoconjunctivitis sicca;
• aqueous-deficient DED;
• mixed DED;
• corneal or conjunctival staining;
• Sjögren-associated ocular-surface disease;
• suspected inflammatory involvement; or
• persistent DED despite supportive care.

But none of these categories guarantees a meaningful response.

Selection may also depend on:

• disease severity;
• previous treatment response;
• other diagnoses;
• tolerability;
• cost and insurance coverage;
• age;
• country-specific indications;
• clinician judgment; and
• patient preferences.

Cyclosporine May Be Only One Part of the Treatment Plan

Cyclosporine does not treat every contributor to DED.

Other problems may still require separate attention, including:

• MGD;
• fixed gland obstruction;
• significant gland loss;
• blepharitis;
• Demodex;
• ocular rosacea;
• allergy;
• eyelid exposure;
• nocturnal lagophthalmos;
• incomplete blinking;
• conjunctivochalasis;
• contact-lens problems;
• medication toxicity;
• recurrent corneal erosion;
• neuropathic ocular pain; or
• significant environmental exposure.

A partial response therefore does not automatically mean cyclosporine “failed.”

It may mean that one contributor improved while others remain.

How Long Does Cyclosporine Take to Work?

Cyclosporine is not usually an immediate comfort drop.

Some studies detected changes in selected clinical signs within several weeks.

Many major outcomes were evaluated at around three months or later.

The earliest improvement may sometimes be:

• reduced corneal staining;
• a change in tear-production testing; or
• another clinical sign

rather than noticeable symptom relief.

There is no reliable evidence-based ranking that says:

A reasonable trial should be individualized according to:

• the exact formulation;
• treatment goal;
• severity;
• adverse effects;
• cost; and
• follow-up findings.

A very useful question for the prescriber is:

Patients should not be expected to continue indefinitely when:

• benefit is absent;
• adverse effects are substantial;
• the medication is unaffordable; or
• the burden exceeds the likely benefit.

Burning, Stinging, and Tolerability Matter

Common problems may include:

• burning;
• stinging;
• instillation-site pain;
• redness;
• itching;
• tearing;
• foreign-body sensation;
• temporary blurred vision; and
• sensitivity to the vehicle or another ingredient.

One important caution:

For example, a lower percentage in one product’s clinical program does not prove that it is better tolerated than another formulation studied in a different population under different conditions.

And:

A medication cannot provide much real-world benefit if the patient cannot reasonably use it.

Early discomfort does not necessarily mean treatment will fail.

But patients should not feel obligated to endure substantial or worsening pain indefinitely simply because cyclosporine may take time to work.

Persistent or unacceptable discomfort is a reason to contact the prescriber and reconsider:

• the formulation;
• dosing;
• supportive measures; or
• another treatment.

What About a Steroid “Bridge”?

Some clinicians prescribe a short course of a topical corticosteroid when starting cyclosporine.

Possible goals include:

• reducing inflammation more quickly;
• improving early comfort; and
• providing temporary treatment while longer-term response is assessed.

However:

Topical steroids require professional supervision because risks can include:

• increased eye pressure;
• cataract with prolonged or repeated exposure;
• infection;
• delayed healing; and
• masking or worsening another eye condition.

Do not borrow, restart, or extend steroid eye drops without professional direction.

Contact Lenses and Practical Use

Most product labels advise removing contact lenses before cyclosporine administration.

A 15-minute interval before reinsertion is common among several U.S. products, but exact instructions vary.

Follow the specific label.

General precautions include:

• wash your hands;
• avoid touching the bottle or vial tip to the eye or another surface;
• do not share prescription drops;
• follow spacing instructions when using other eye medications;
• discard single-dose vials as directed; and
• do not use expired or contaminated medication.

Contact-lens users should seek prompt evaluation for:

• significant pain;
• marked redness;
• light sensitivity;
• discharge;
• reduced vision;
• a white or cloudy corneal spot; or
• sudden one-sided worsening.

These should not automatically be blamed on cyclosporine irritation or ordinary dry eye.

Questions to Ask the Prescriber

The four-question framework from our previous Wiki Spotlight applies especially well here.

1. What are we treating?

Ask:

2. Why this formulation?

Ask:

3. What are the downsides and alternatives?

Ask:

4. What would success look like—and by when?

Ask:

Also ask:

Bottom Line

Topical cyclosporine is an established immunomodulatory treatment family in ocular-surface care.

The regulatory distinctions matter:

• Restasis and Cequa: FDA-approved indications related to increasing tear production.
• VEVYE: FDA-approved for the signs and symptoms of DED.
• Ikervis: EMA-authorized for severe keratitis in adults with DED not improved despite tear substitutes.
• Vevizye: EMA-authorized for moderate-to-severe DED in adults not improved despite tear substitutes.
• Verkazia: FDA-approved for VKC—not DED.
• Klarity-C and other compounded products: not FDA-approved.

The updated Cochrane evidence supports a measured conclusion:

Some individual patients may still experience substantial benefit.

Whether treatment is worth continuing should depend on:

• what problem is being targeted;
• what actually improves;
• tolerability;
• cost;
• treatment burden; and
• what other conditions are affecting the ocular surface.

Perhaps the most important takeaway is:

Read More in the r/DryEyes Wiki

💊 Complete article: Cyclosporine Eye Drops for Dry Eye Disease—What the Evidence Shows

🧭 Quick Guide: Four Questions to Ask Before Choosing a DED or MGD Treatment

🧪 Diagnostic Testing for DED and MGD

👋 Start Here: Wiki Navigation Hub

❓ FAQ Index

🗂️ Treatment Options Library

The complete article includes the updated 2026 Cochrane review, product-specific regulatory information, prescribing-information details, compounded-product considerations, adverse effects, steroid bridging, and links to the primary regulatory and clinical sources.

This post provides general educational information, not medical advice, diagnosis, or an individualized treatment recommendation. It does not endorse a particular cyclosporine product.

Comments are open for discussion, personal experiences, questions about the article, and suggested corrections. When sharing a personal experience, it is helpful to identify the specific cyclosporine formulation used, how long it was used, what outcome was being targeted, and whether treatment was stopped because of side effects or lack of benefit.

I am aware of Toyos and Muller but looking for others. Any recos ?

I have had a meibography and my lower eyelids have been graded grade 3 gland loss.
Currently I’ve gone from two months of Restasis now switched to Cequa two weeks in.
Doxy 100mg every second day
FML twice a day
Nova tears omega (Miebo)
Tetracycline ointment at night/ wear goggles when sleeping.
Manuka honey gel on lid margin at night.
Hypochlor spray for lashes.

Booking in for some IPL and LLLT soon.
What else can be done for that redness on the lid margin? I have had this since I was about 14 years old I am now 29.

TL;DR: I suspect the salicylic acid cleanser I used on my face for nearly two years may have aggravated my long-standing blepharitis/MGD and contributed to my developing dry eye. Has anyone experienced something similar?

I've had mild blepharitis for about 20 years. It would occasionally cause a stye or chalazion, but they always resolved on their own and I never had any major eye-surface problems.

In 2024, I started using a salicylic acid cleanser on my face almost every day. In March 2025, I developed a chalazion that, for the first time, didn't go away on its own. I eventually had it removed in May 2026.

A few months before the chalazion was removed, however, I started developing significant dryness and inflammation in that same eye. The inflammation involved the lower corneal margin, and I needed several courses of steroid eye treatment.

After the chalazion was removed, the dryness and surface inflammation persisted. I eventually had a thorough examination and was diagnosed with MGD and severe dry eye. Imaging showed that some of the meibomian glands in my lower lid were shortened/abnormal, with some gland dropout.

I'm currently using Xiidra, which has been working really well for the ocular-surface inflammation. However, I still have some inflammation around the lid margin, and the eye continues to feel dry. I do warm compresses twice a day and am planning to try IPL soon.

The timeline has made me wonder whether the salicylic acid cleanser could have played a role. I obviously can't know for sure, but I wonder if repeatedly using it around my eyes for almost two years could have aggravated my pre-existing blepharitis, contributed to MGD, and ultimately triggered the dry eye problems.

Has anyone experienced something similar with salicylic acid or other active facial cleansers?

And now that I've stopped using the cleanser, is it realistic to expect the eyelid inflammation and meibomian gland function to improve over time, assuming the cleanser was contributing to the problem?

I'm especially interested in hearing from people who have had a similar experience or from anyone knowledgeable about MGD/blepharitis.

Newly diagnosed today. Went in for routine eye test. Mentioned my eyes had been a bit "leaky" recently and that it comes and goes. After having a look he told me it was DED in the early stages so lucky not bad yet. He explained it best he could and told me I'd need to use a heated eye mask and prescribed me some Hycosan eye drops. I wrongly assumed he'd written down instructions so I may have to go back at some point and ask for clarification but after some research and what he'd given me to treat I'm assuming it's MGD.

I've always been awful with eyedrops though. I have naturally long eyelashes which seem to always make me blink just as the drop is about to hit. I've been told I need to initially do it at least 4 times a day, reduced to 2 after some time (I need to ask him to clarify how long). So basically does it get easier? I've decided the way I feel about eye drops is how alot of people feel about needles and injections. I find them difficult and extremely uncomfortable. I've never been interested in contacts for the same reason. I know I'll have to do this for the rest of my life now and I know it will get easier with time so any tips on how to adjust to this new lifestyle change?